Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor
Jennifer Duong, Christopher E. Pope, Hillary S. Hayden, Carson J. Miller, Stephen J. Salipante, Steven M. Rowe, George M. Solomon, David P. Nichols, Lucas R. Hoffman, Michael R. Narkewicz, Nicole Green
Topics & Concepts
IvacaftorCystic fibrosisMedicineCystic fibrosis transmembrane conductance regulatorDysbiosisPathogenesisLiver diseaseDiseaseInflammationGastroenterologyInternal medicineImmunologyCystic Fibrosis Research AdvancesGut microbiota and healthLiver Disease and Transplantation